Futura Medical plc (FUM) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Futura Medical PLC investor presentation. Throughout this quarter presentation, investors will be in this and any mode. Questions are encouraged and they can be submitted at any time by the Q&A tab situated in the right corner of your screen. Just simply type in your questions and press send. The company may not be in a position to answer every question it receives in the meeting itself. However, the company can review all the questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to James Bader, CEO. Good morning to you, sir. Good morning, everyone, and welcome to Futura Medical's year-end results presentation for the period ending 31st of December 2024. I am James Barlow, CEO of Futura, and I'm joined today by Anja Hildreth, Futura's Finance Director and COO, and also Ken James, Executive Director and Futura's Head of R&D. Futura specializes in the development and commercialization of innovative sexual health products across the world. Our lead product is Roxon, a clinically proven breakthrough treatment for erectile dysfunction. Our key area of expertise is in topically delivered gel formulations. For the last year, I have said consistently that we saw 2024 as a year of execution, and I'm delighted to say this has proved very much the case, with the company delivering on our strategic priorities and in particular growing revenue and our maiden profit. Eroxon is now on sale both online and in retail pharmacies in at least 15 countries, including the USA, with further launches expected during 2025. We continue to see a strong sell-in to retailers through our commercial partners, but as previously mentioned, with any new OTC ...